

Disclosures

Personal Commercial (10)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Bayer Healthcare Pharmaceuticals	Research/Research Grants ‡ Bleeding Risk Score	None (\$0)	Prevention
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Genentech, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Idorsia	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
New Amsterdam	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Novo Nordisk Inc.	Research/Research Grants	None (\$0)	Prevention
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Siemens	Consultant Fees/Honoraria	Significant (>= \$5,000)	Acute Coronary Syndromes

Additional Personal Commercial Disclosures for Education Activities (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Agepha	Consultant Fees/Honoraria	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Acute Coronary Syndromes
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Vectura	Consultant Fees/Honoraria	Significant (>= \$5,000)	Vascular Medicine

Personal Organizational or Other Non-Commercial (4)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
ACC	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
American Heart Association	Research/Research Grants	None (\$0)	General Cardiology
FDA	Research/Research Grants	None (\$0)	General Cardiology
National Institutes of Health	Research/Research Grants	None (\$0)	Prevention

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2024	Cholesterol	Plaintiff ‡ none	Lawsuit on behalf of the US FTC for a product with purported health benefit.	Significant (>= \$5,000)
2024	Diabetes	Defendant ‡ none	Challenge to a patent for a diabetes medication	Significant (>= \$5,000)

Agreement

Certified Education Attestation | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/2/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.